News and Announcements
Malaysian Healthtech Startup Naluri Bags $5M in Series A Funding
- Published July 07, 2021 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Malaysian-based digital service provider Naluri Hidup announced on Wednesday the closing of a $5 million Series A funding round.
Besides the cornerstone investor, Singapore’s Intergra Partners, other strategic investors who participated in the fund include: Duopharma Biotech Bhd, Pathology Asia (via Biomark), and venture capital firm M Venture Partners, who were part of the company’s preceding round, Naluri said in a statement.
Naluri also added new investors to its cap table – Sumitomo, Corporation Equity Asia, Palm Drive Capital from New York, and INP Capital from Vancouver, Canada. The company also gain support from the Hibiscus Fund, a venture capital fund managed by Malaysia’s RHL Ventures and Korea’s KB Investment that are part of the government’s Dana Penjana National Programme.
Click here to read the full article by Deal Street Asia.
About Naluri Hidup Sdn Bhd
Naluri is a human-driven, Artificial Intelligence-augmented digital chronic disease management program that delivers quantifiable health outcomes and helps healthcare payors save on avoidable healthcare costs that uniquely addresses physical and mental health risks together, through structures, multi-disciplinary behavioural health coaching in a way that is twice as effective as medication alone and much more accessible.
Naluri has developed a distinctive model that solves challenges of existing digital health solutions, that is commercially validated. Its digital solution offers comparable levels of clinical effectiveness as medication, and ten-times lower cost that in-person therapy.
Naluri’s model aims to completely reimagine the current healthcare landscape and define the next generation (Healthcare 3.0) model beyond tele-health consultation services for chronic disease management. It has pioneered coordinated multi-disciplinary health coaching instead of a single specialist health coach model (Livongo) and using analytics and business process innovation to do it in a most cost – efficient manner (affordable by emerging markets).
Application of deep technology to quantify patient behaviours and mindsets to develop decision support tools and 10X productivity and effectiveness of coaches, leads to proven real-world clinical outcomes worth USD950million when compared to administration of drugs for clinical purposes.
Company Updates
The Index Approach in Early-Stage Venture Capital: Reconsidered
The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]
The Future Is Now: The Evolution of Dealflow with Wholesale Investor
If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]
Investability of a Startup: A Comprehensive Guide for Angels and High-Net Worth Investors
Venturing into the Startup Scene Let’s dive into the intriguing world of startups. It’s a thrilling ride, isn’t it? Like finding a pearl in an ocean, spotting a promising startup amidst a sea of businesses is no easy task. This guide aims to light the way, focusing on the “The Investability of a Startup: 7 […]
Backed By Leading Investment Groups and Family Offices
